AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3786999
Drug: Dose-finding trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-finding trials
Trial: 16628140
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg orally twice per day for 3 days)
Trial: 16628140
Drug: Midazolam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2.5 mg and 1 mg intravenously)
Trial: 1486974
Drug: Inhaled glucocorticosteroid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled glucocorticosteroid, budesonide 400 micrograms b.i.d.
Trial: 3721055
Drug: Intramuscular combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular combination of buprenorphine (0.3 mg)/naloxone (0.2 mg)
Trial: 27169564
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg tablets
Trial: 27169564
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg tablets
Trial: 27169564
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg tablets
Trial: 27169564
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg and 400 mg tablets
Trial: 20113414
Drug: 8% lidocaine
RxNorm normalized name: LIDOCAINE 18 g in 100 g TOPICAL CREAM [Tattoo Numbing Cream 18% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% lidocaine spray
Trial: 20113414
Drug: lidocaine patch
RxNorm normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine patch
Trial: 16816482
Drug: Active vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitamin D3 therapy
Trial: 16816482
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Active vitamin D3 and bisphosphonates
Trial: 9952390
Drug: Standard-dose ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose ivermectin
Trial: 9952390
Drug: High-dose ivermectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ivermectin
Trial: 2337571
Drug: 5% eutectic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% eutectic mixture of lignocaine (100 mg) and prilocaine (100 mg) plus emulsifier (EMLA)
Trial: 2337571
Drug: 10% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% lignocaine spray (200 mg)
Trial: 26001948
Drug: Zoledronate 5
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate 5 mg intravenous infusion
Trial: 9432896
Drug: Combined spinal-epidural
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal-epidural anesthesia with 20 mg of 1% lidocaine and maintained with 2% lidocaine through an epidural catheter (Group I)
Trial: 9432896
Drug: Spinal plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal plain 20 mg of 0.5% bupivacaine (Group II)
Trial: 9432896
Drug: Initial dose
RxNorm normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of plain 0.5% bupivacaine 3 ml (15 mg) with an incremental dose of 3 ml (15 mg) (Group III)
Trial: 9432896
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of anesthetic (Group I)
Trial: 9432896
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of anesthetic (Group II)
Trial: 9432896
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of anesthetic (Group III)
Trial: 7871065
Drug: Three IM
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 12-h intervals
Trial: 7871065
Drug: Three IM
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 24-h intervals
Trial: 7871065
Drug: Three IM
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 48-h intervals
Trial: 7871065
Drug: Three IM
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three IM morphine injections (18 mg/70 kg) spaced at 72-h intervals
Trial: 7871065
Drug: Single IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IM morphine pretreatment (18 mg/70 kg) followed by naloxone challenge (10 mg/70 kg IM)
Trial: 2878712
Drug: Bethanechol chloride
RxNorm normalized name: Bethanechol Chloride
DrugBank: Bethanechol (DB01019)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bethanechol chloride (Urecholine) infused intracerebroventricularly with an Infusaid continuous infusion pump
Trial: 27464461
Drug: Freeze-dried strawberry
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried strawberry powder (FDSP) 50 g daily for 1 week
Trial: 24981605
Drug: Medication reconciliation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reconciliation performed at discharge by a hospital pharmacist with communication to the community pharmacist.
Trial: 20863237
Drug: Desensitizer toothpaste
RxNorm normalized name: Fluorimax Sensitive Toothpaste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizer toothpaste and GaAlAs (diode) laser therapy
Trial: 18794896
Drug: Ileal fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal fat perfusion (3 g and 9 g safflower oil)
Trial: 18794896
Drug: Ileal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal placebo infusion after fat-free liquid breakfast (treatment C)
Trial: 12139807
Drug: NPTS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPTS with reticulated hyaluronic acid implant
Trial: 11563408
Drug: Ganciclovir 2000
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir 2000 mg tid taken within 30 minutes of a meal
Trial: 11563408
Drug: Ganciclovir 2000
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ganciclovir 2000 mg tid taken on an empty stomach
Trial: 2031393
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 40 mcg prostaglandin E1
Trial: 7111875
Drug: Intranasal phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal phenylephrine (0.25% solution)
Trial: 30297499
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen (10 mg/kg every 6 hours until 24 hours after the first convulsion if fever >38.0°C)
Trial: 27092831
Drug: MVA-BN-Filo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN-Filo (1 × 10^8 median tissue culture infective dose)
Trial: 22336721
Drug: Glutamate (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate (0.5 mol/L) injection into the masseter muscle
Trial: 22336721
Drug: Co-injection of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-injection of ketamine (20 mmol/L) with glutamate
Trial: 17872679
Drug: Single-dose intrathecal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intrathecal narcotics (ITN) with a combination of 2.5 mg of bupivacaine, 25 microg of fentanyl, and 250 microg of morphine.
Trial: 3513528
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg guanfacine
Trial: 3513528
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg guanfacine
Trial: 9766253
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test at room temperature (0.1 U per kg of BW, i.v.)
Trial: 9766253
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance test under increased ambient temperature for 45 min before and after insulin injection
Trial: 26686957
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg per day
Trial: 24452393
Drug: TAS-114 single
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-114 single dose (6, 18, 60, 150, and 300 mg)
Trial: 24452393
Drug: TAS-114 multiple
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-114 multiple doses (14 days consecutively)
Trial: 18683218
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg monthly for 1 year)
Trial: 9293855
Drug: Fludarabine (FLU)
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine (FLU) as salvage chemotherapy, 25 mg/m2 for 5 consecutive days, repeated every 28 days for a maximum of 6 cycles.
Trial: 9293855
Drug: Alpha-interferon (alpha-IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-interferon (alpha-IFN) maintenance therapy, 3x10^6 units 3 times per week until disease progression.
Trial: 9293855
Drug: Alpha-interferon (alpha-IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-interferon (alpha-IFN) maintenance therapy vs no further therapy after FLU response.
Trial: 9332921
Drug: Diltiazem (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.1 mg/kg per h)
Trial: 2783492
Drug: Acupuncture‐like TENS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture‐like TENS treatment (10-minute treatment bilaterally to five acupuncture points on the auricle)
Trial: 21806694
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo pill)
Trial: 31783028
Drug: 2% Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Vitamin C solution (VCS)
Trial: 31783028
Drug: 5% Sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Sodium thiosulfate solution (STS)
Trial: 17055858
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (NS)
Trial: 30641692
Drug: Probiotic supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplements (7 viable strains: Lactobacillus, Bifidobacterium, and Streptococcus) for 6 weeks
Trial: 25515658
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) at a dosage of 30 Gy in 10 fractions
Trial: 21332742
Drug: 1% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% citric acid solution (pH 2.3) for 20 minutes
Trial: 16789982
Drug: ASA and
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA and Codeine combination
Trial: 7954555
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous isosorbide dinitrate
Trial: 30019829
Drug: Buccal approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal approach (control group)
Trial: 25500887
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thymocyte globulin (ATG) 2.5 mg/kg intravenously followed by pegylated G-CSF 6 mg subcutaneously every 2 weeks for 6 doses
Trial: 25500887
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thymocyte globulin (ATG) and pegylated G-CSF
Trial: 21395446
Drug: Weekly Fast
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Fast Facts and Concept (FFAC) e‐mails, 32 e‐mails over 32 weeks
Trial: 21395446
Drug: Weekly Fast
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly Fast Facts and Concept (FFAC) e‐mails
Trial: 17190104
Drug: 4G-beta-D-galactosylsucrose (lactosucrose;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4G-beta-D-galactosylsucrose (lactosucrose; LS) 6.0 g twice daily
Trial: 17190104
Drug: Placebo (maltose;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltose; 6.0 g twice daily)
Trial: 14707396
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg once daily (o.d.)
Trial: 14707396
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 microg twice daily (b.i.d.)
Trial: 16817839
Drug: Pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 20 mg o.d.
Trial: 9444014
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg single dose
Trial: 10023867
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 0.5 mg/kg/day
Trial: 10023867
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 1.0 mg/kg/day
Trial: 10023867
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 2.0 mg/kg/day
Trial: 10023867
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) (any dose)
Trial: 401759
Drug: Trental 400
RxNorm normalized name: Trental 400mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trental 400 (400 mg Pentoxifylline per tablet), 3 tablets daily for 3 months
Trial: 401759
Drug: Comparative formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative formulation (2.4 mg adenosine per tablet), 3 tablets daily for 3 months
Trial: 31969713
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% spray, 1-2 applications (0.1-0.2 ml) for 8 weeks, containing 5-10 mg of lidocaine
Trial: 31969713
Drug: Placebo (alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (alcohol 40% spray), 1-2 applications (0.1-0.2 ml) for 8 weeks
Trial: 28546852
Drug: Resveratrol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (1000 mg/day for 28 days)
Trial: 23532686
Drug: ASA+ER‐DP 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA+ER‐DP 25 mg/200 mg BID alone (Treatment A)
Trial: 23532686
Drug: ASA+ER‐DP 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA+ER‐DP 25 mg/200 mg BID + omeprazole 80 mg QD (Treatment B)
Trial: 23532686
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg QD alone (Treatment C)
Trial: 23532686
Drug: Omeprazole 80
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 80 mg QD + ASA+ER‐DP 25 mg/200 mg BID (Treatment D)
Trial: 19071979
Drug: Take‐home methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take‐home methadone doses contingent on cocaine‐ and opiate‐negative results (THM)
Trial: 19071979
Drug: Take‐home methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take‐home methadone doses for cocaine‐ and opiate‐negative results and monetary‐based vouchers contingent on cocaine‐negative urinalysis results (THM + V)
Trial: 12817520
Drug: Etoricoxib (5-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (5-500 mg single doses and 25-150 mg multiple doses)
Trial: 12817520
Drug: Etoricoxib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib (up to 150 mg qd)
Trial: 11165311
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate administration
Trial: 6516935
Drug: Rational-emotive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-emotive therapy without imagery (RET)
Trial: 6516935
Drug: Rational-emotive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-emotive therapy with imagery (REI)
Trial: 6516935
Drug: Rational-emotive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-emotive therapy (RET) and Rational-emotive therapy with imagery (REI)
Trial: 29765212
Drug: Conjugated Linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated Linoleic Acid (CLA) supplement, 3.2 g daily for 6 weeks
Trial: 29765212
Drug: Placebo, 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3.2 g daily for 6 weeks
Trial: 27189289
Drug: AST-120 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120 (6 g/day) for 6 months
Trial: 23607203
Drug: Preoperative chemoradiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiotherapy (including pre‐ and postoperative irradiation, surgery, adjuvant chemotherapy)
Trial: 23607203
Drug: Surgery with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery with adjuvant chemotherapy
Trial: 20105041
Drug: P1+ (preserved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1+ (preserved first-phase insulin secretion)
Trial: 20105041
Drug: P1- (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1- (no first-phase insulin secretion)
Trial: 16257791
Drug: 3 months'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months' androgen deprivation (3.6 mg goserelin subcutaneously every month and 250 mg flutamide orally three times a day)
Trial: 9633847
Drug: Multiple cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple cycles of high-dose chemotherapy with hematopoietic support (colony-stimulating factors and peripheral blood progenitor cells)
Trial: 9633847
Drug: Multiple cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple cycles of high-dose chemotherapy
Trial: 7493828
Drug: Conformal brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal brachytherapy (CB) with HDR boost implants (5.5 Gy, 6 Gy, 6.5 Gy)
Trial: 7493828
Drug: Interactive online
RxNorm normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interactive online planning system for HDR treatment
Trial: 6127890
Drug: Prenalterol 20‐200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol 20‐200 mg daily (slow‐release tablet preparation)
Trial: 27254743
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (1000 IU daily)
Trial: 27254743
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (1000 IU daily) + Calcium (1200 mg daily)
Trial: 27603424
Drug: BCG monotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG monotherapy (Connaught 120 mg, 6 weekly instillations followed by 10 instillations)
Trial: 27603424
Drug: Alternating therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating therapy with mitomycin C (MMC 40 mg, 6 weekly instillations followed by 10 instillations of BCG)
Trial: 15214141
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation (400 ml, 400 kcal) daily for six months
Trial: 15214141
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 ml) daily for six months
Trial: 12720592
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplementation
Trial: 9619529
Drug: Intra-nasal buserelin
RxNorm normalized name: buserelin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-nasal buserelin (doses ranged from a single 25 microg dose to 100 microg every 4 h for 20 h)